AAM Statement — Restricting Patent Settlements Hurts Patients
Banning Patent Litigation Settlements Will Keep Biosimilars and Generic Drugs Off the Market No Patient Benefit - Only Helps Big Pharma Companies Abusing the Patent System
MEDIA ADVISORY
AAM Statement on PACED Act of 2018
MEDIA ADVISORY
“With everyone from patients to the president demanding action on drug pricing, AAM welcomes the introduction of the Preserving Access to Cost Effective Drugs (“PACED”) Act of 2018. This legislation will put a stop to the recent anticompetitive ploy made infamous by Allergan when it rented sovereign immunity from a Native American tribe to avoid legitimate review of disputed patents by the U.S. Patent and Trademark Office (PTO).
AAM Position Paper: HHS 180-Day Exclusivity Proposal
Our position paper addresses the HHS FY19 Budget as released on Feb 19, 2018. AAM holds:
Seeking Asylum for Its Patents on Tribal Lands: The Latest Brand-Name Drug Company Strategy to Preserve Monopoly Pricing
In September 2017, Allergan, the maker of Restasis, adopted an unprecedented strategy: it paid the St. Regis Mohawk Tribe millions of dollars to rent its tribal sovereign immunity in a blatant effort to shield the patents on Restasis from review. The maneuver has deservedly attracted attention in the media (see The New Yorker and Fortune) and, now, the House Judiciary Committee.
Allergan Deal - The Latest Ploy
In September 2017, Allergan adopted an unprecedented strategy: it paid millions of dollars to rent the sovereign immunity of a Native American Tribe, and now claims that its patents are beyond the reach of the U.S. Patent and Trademark Office (PTO). In effect, Allergan's patents are seeking asylum on tribal lands.
AAM White Paper: Renting Tribal Immunity to Evade IPR Review of Pharmaceutical Patents
For more than four decades, U.S. Patent and Trademark Office (PTO) review of issued patents has been considered a vital component of a healthy patent system, and Congress has worked to improve that review system to systematically eliminate invalid, competition-killing patents. The rental of Native American sovereign immunity by brand name drug companies is a transparent attempt to thwart this process.
Support the CREATES Act and Help Patients Win
“The objective is to win: fairly, squarely, decently, win by the rules, but still win.” – Vince Lombardi
When it comes to prescription medicines, patients win when companies innovate new cures and treatments. Patients also win when more affordable generic versions of those medicines enter the market. Unfortunately, some brand manufacturers aren’t playing by the rules.
Stop Big Pharma Patent Abuse
Big Pharma has consistently created market monopolies at the expense of patients’ health and pocketbooks. The IPR process is one way to stop Big Pharma and provide low-cost generic medicines to patients. Learn more: https://www.stoprxpatentabuse.com/